Depletion of High-Content CD14⁺ Cells from Apheresis Products Is Critical for the Successful Transduction and Expansion of CAR T Cells during Large-Scale cGMP Manufacturing

Investigators found that high CD14+ cell content posed a challenge for manufacturing CAR T cells especially in patients with non-Hodgkin’s lymphoma and multiple myeloma due to the non-specific phagocytosis of the magnetic beads used to activate CD3+ T cells.